ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.

Biotechnology

Health Care

Life Sciences

Medical Devices

Therapeutics

ProKidney Corp.

Bruce Culleton

QC Director, Analytical Science And Technology (asat)

Carla Poulson

Kathleen Conde

Anu Biswas

Brian Buckley

James Coulston

Clarence W. Baker

Nancy Fuselli

McKenzie Christopher Pitts

Mary M. Weger

Emily Butler

Aparna Sahoo

Todd Girolamo

Nikhil Pereira-Kamath

The Research and Development team at ProKidney Corp. is responsible for advancing the company's innovative cellular therapy solutions for Chronic Kidney Disease (CKD). This team conducts pioneering research, optimizes bioprocesses, and develops new methodologies to enhance the efficacy and safety of ProKidney's lead product candidate, REACT™. Their work includes rigorous experimentation, process optimization, and ensuring compliance with regulatory standards to support clinical trials and the eventual commercialization of breakthrough therapies.

Research and Development

Clinical and Quality Assurance Team

Leadership Team

Manufacturing and Supply Chain

Research and Development

About

Team members

Other teams at ProKidney Corp.

Clinical and Quality Assurance Team

Leadership Team

Manufacturing and Supply Chain